Mesoblast Limited (MEOBF)
| Market Cap | 2.46B +33.1% |
| Revenue (ttm) | 120.25M +599.2% |
| Net Income | -57.50M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 1.530 |
| Previous Close | 1.140 |
| Day's Range | 1.530 - 1.530 |
| 52-Week Range | 1.140 - 2.050 |
| Beta | 0.91 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 17, 2026 |
About Mesoblast
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is i... [Read more]
Financial Performance
In fiscal year 2026, Mesoblast's revenue was $120.25 million, an increase of 599.21% compared to the previous year's $17.20 million. Losses were -$57.50 million, -43.71% less than in 2025.
Financial StatementsNews
Mesoblast Slides: FY 2026
Mesoblast has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 9, 2026.
Mesoblast Shares Drop 6% as Stem Cell Developer Slides in Risk-Off Trade Despite 44% Jump in Ryoncil Revenue
Mesoblast shares fell more than 6% amid a broad market pullback, despite 44% quarterly growth in Ryoncil revenue and an 86% reduction in operating cash spend.
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion l...
Mesoblast Limited Announces Board Retirements and Committee Leadership Changes Ahead of 2026 Annual General Meeting
Mesoblast Limited announced rotational changes and the retirement of certain members of its Board. After 12 years of serving on the Board since 2014, Mr William Burns will retire from the Board at the...
Mesoblast announces changes, retirement of certain members of its Board
Mesoblast (MESO) announced rotational changes and retirement of certain members of its Board, and reiterated its intention to add new members with the requisite global commercial experience in the bio...
Mesoblast Board Changes
NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and r...
Mesoblast Limited Reports first quarter FY2027 Activity with 44% increase in net revenues
Mesoblast Limited provided its activity report for the first fiscal quarter ended September 30, 2026. Financial highlights included a 44% increase in net revenues and an 86% improvement in net operati...
Mesoblast Stock Jumps 17% on Nasdaq as Ryoncil Sales Climb 44% and Cash Burn Collapses in Quarterly Update
Mesoblast shares surged in Australia and the US after Ryoncil revenue rose 44%, quarterly cash spending fell sharply and the company reported progress on adult trials and pipeline treatments.
Mesoblast Shares Soar 23% as Ryoncil Revenue Jumps 44% and Cash Burn Plunges 86% in Upbeat Quarterly Update
Mesoblast shares jumped 23.4% after quarterly Ryoncil revenue rose 44% to US$28 million and operational cash spending fell 86% to US$2.1 million.
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for t...
Mesoblast Earnings release: Q1 2027
Mesoblast released its Q1 2027 earnings on October 28, 2026, summarizing the period's financial results.
Mesoblast Earnings release: Q1 2027
Mesoblast released its Q1 2027 earnings on October 28, 2026, summarizing the period's financial results.
Mesoblast receives FDA approval for potency assay to release Ryoncil product
Mesoblast (MESO) announced that it has received approval from the United States Food and Drug Administration, FDA, to implement a new potency assay, T-cell Proliferation Inhibition BioAssay, TIBA, for...
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received ap...
Mesoblast price target raised to $39 from $35 at Piper Sandler
Piper Sandler raised the firm’s price target on Mesoblast (MESO) to $39 from $35 and keeps an Overweight rating on the shares. Net Ryoncil revenues were $115M in FY26, and…
Mesoblast Reports Substantial Revenue Growth to US$120M
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesobla...
Mesoblast H2 Earnings Call Highlights
Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell therapy...
Mesoblast Earnings Call Transcript: H2 2026
FY 2026 saw $115M net revenue and a 44% reduction in net loss, driven by RYONCIL's successful launch and broad adoption. Major phase III trials in adult GVHD, chronic low back pain, and heart failure are progressing, with double-digit revenue growth expected next year.
Mesoblast Annual report: H2 2026
Mesoblast has published its H2 2026 annual report on August 26, 2026.
Mesoblast Slides: H2 2026
Mesoblast has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 26, 2026.
Mesoblast Earnings release: H2 2026
Mesoblast released its H2 2026 earnings on August 26, 2026, summarizing the period's financial results.
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain, CLBP, associated with the...
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed pa...
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain...
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its...